Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP388B monotherapy and combination study in advanced solid tumors
jRCT2031260376Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of ASP388B in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) and 3 more (5 arms), sponsored by Astellas Pharma. Primary endpoints: Incidence of dose-limiting toxicities, Treatment-emergent adverse events and 5 more. Started Sep 2026; status: recruiting.
02
Drugs
ASP388B
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)metastatic castration-resistant prostate cancer (mCRPC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on jRCT2031260376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260376.